灌注MRI作为鉴别胶质瘤与脑转移瘤的诊断生物标志物:系统综述与Meta分析
该系统综述与Meta分析纳入截至2017年10月3日的18项研究共900例患者,评估灌注MRI鉴别胶质瘤与脑转移瘤的诊断性能。汇总敏感度为90%(95%CI 84-94%),特异度为91%(95%CI 84-95%),层次汇总受试者工作特征曲线下面积为0.96(95%CI 0.94-0.98)。亚组分析仅纳入胶质母细胞瘤患者时,汇总敏感度为92%(95%CI 84-97%),特异度为94%(95%CI 85-98%)。作者结论认为现有证据支持使用灌注MRI鉴别胶质瘤与脑转移瘤。
要点
- 灌注MRI鉴别胶质瘤与脑转移瘤的汇总敏感度90%、特异度91%,AUC 0.96。
- 仅纳入胶质母细胞瘤的亚组汇总敏感度92%、特异度94%,诊断性能优异。
- DSC来源的瘤周rCBV是相对经过较好验证的参数。
核心结论
- 尽管使用了多种灌注MRI技术,现有证据支持使用灌注MRI鉴别胶质瘤与脑转移瘤,尤其对胶质母细胞瘤与脑转移瘤的鉴别表现出优异的诊断性能。
研究设计与样本
- 系统综述与Meta分析,检索Ovid-MEDLINE和EMBASE数据库至2017年10月3日,纳入18项研究共900例患者,采用层次逻辑回归模型获得汇总敏感度和特异度估计。
诊断标准与关键数值
- 灌注MRI鉴别胶质瘤与脑转移瘤的汇总敏感度90%(95%CI 84-94%)、汇总特异度91%(95%CI 84-95%),层次汇总ROC曲线下面积0.96(95%CI 0.94-0.98);仅纳入胶质母细胞瘤患者的亚组汇总敏感度92%(95%CI 84-97%)、汇总特异度94%(95%CI 85-98%)。
临床应用与阅片要点
- Meta回归显示研究人群中胶质瘤所占比例和研究设计是影响研究异质性的显著因素;DSC来源的瘤周rCBV是相对经过较好验证的参数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Differentiation of glioma from brain metastasis is clinically crucial because it affects the clinical outcome of patients and alters patient management. Here, we present a systematic review and meta-analysis of the currently available data on perfusion magnetic resonance imaging (MRI) for differentiating glioma from brain metastasis, assessing MRI protocols and parameters.
METHODS: A computerised search of Ovid-MEDLINE and EMBASE databases was performed up to 3 October 2017, to find studies on the diagnostic performance of perfusion MRI for differentiating glioma from brain metastasis. Pooled summary estimates of sensitivity and specificity were obtained using hierarchical logistic regression modelling. We conducted meta-regression and subgroup analyses to explain the effects of the study heterogeneity.
RESULTS: Eighteen studies with 900 patients were included. The pooled sensitivity and specificity were 90% (95% CI, 84-94%) and 91% (95% CI, 84-95%), respectively. The area under the hierarchical summary receiver operating characteristic curve was 0.96 (95% CI, 0.94-0.98). The meta-regression showed that the percentage of glioma in the study population and the study design were significant factors affecting study heterogeneity. In a subgroup analysis including patients with glioblastoma only, the pooled sensitivity was 92% (95% CI, 84-97%) and the pooled specificity was 94% (95% CI, 85-98%).
CONCLUSIONS: Although various perfusion MRI techniques were used, the current evidence supports the use of perfusion MRI to differentiate glioma from brain metastasis. In particular, perfusion MRI showed excellent diagnostic performance for differentiating glioblastoma from brain metastasis.
KEY POINTS: • Perfusion MRI shows high diagnostic performance for differentiating glioma from brain metastasis. • The pooled sensitivity was 90% and pooled specificity was 91%. • Peritumoral rCBV derived from DSC is a relatively well-validated.
引用
- Suh CH, Kim HS, Jung SC, et al. Perfusion MRI as a diagnostic biomarker for differentiating glioma from brain metastasis: a systematic review and meta-analysis. Eur Radiol. 2018. PMID: 29619517. doi:10.1007/s00330-018-5335-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。